# Evaluation of Hypoxia in Primary Melanoma

> **NCT06831071** · — · RECRUITING · sponsor: **Yana Najjar** · enrollment: 50 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Pimonidazole

## Key facts

- **NCT ID:** NCT06831071
- **Lead sponsor:** Yana Najjar
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-09
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06831071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06831071, "Evaluation of Hypoxia in Primary Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06831071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*